AAMC’s testosterone explainer separates hormone functions from treatment benefits, with context on trial findings, diagnosis and risks.
On October 13, 2026, the Association of American Medical Colleges (AAMC) published Patrick Boyle’s AAMCNews explainer, “Testosterone treatments: Weighing benefits and doubts.” The report examines testosterone’s established functions and the mixed evidence for treating people who do not have confirmed low levels.
This article is for informational purposes only and is not medical advice. Personal decisions about diagnosis and treatment require a qualified clinician.
AAMC describes testosterone as contributing to several important functions. These include sex drive and reproduction as well as puberty-related changes and the maintenance of muscle and bone.
Those functions help explain why extremely low testosterone can matter medically. They do not establish that giving additional testosterone will improve every related symptom or produce broader health benefits. The hormone’s normal role and the effects of treatment are separate questions.
According to the AAMC explainer, extremely low levels can contribute to:
This list describes problems associated with very low levels. It is not a symptom-based diagnosis. AAMC notes that identifying hypogonadism varies with patient characteristics and that no single standard measurement applies to every patient.
For someone researching fatigue or sexual symptoms, the distinction matters. Understanding that testosterone has a role in a body system is a starting point. Establishing whether a particular health concern reflects testosterone deficiency requires clinical assessment.
A useful way to read the report is to separate two questions: what does testosterone do in the body, and what happens when clinicians prescribe it? The first concerns normal physiology. The second concerns measured treatment outcomes in a defined group of patients.
For example, testosterone’s role in sexual function does not by itself establish how much a particular person’s sexual symptoms would improve with treatment. That question depends on the clinical evidence and the condition being treated. Our discussion of testosterone and sexual desire provides related context for readers focused on that concern.
AAMC also describes increased patient interest in testosterone and online promotion around fatigue, libido, muscle growth and mood. Popularity is a different kind of information from treatment effectiveness. More requests or prescriptions do not establish that the expected benefits have been demonstrated.
The explainer draws on earlier research rather than presenting a newly completed clinical trial. A central example is the Testosterone Trials, funded by the National Institutes of Health and conducted from 2009 through 2015 in men with hypogonadism.
AAMC reports that these trials found improvements in:
The report also describes little or no improvement in energy or cognitive function. This is a mixed set of outcomes rather than a uniform improvement across all areas of health.
The practical point is that each outcome deserves its own assessment. A finding about bone density does not answer a question about concentration. A finding about sexual function does not establish an energy benefit. Treating the results as one broad success claim would lose the distinctions reported by AAMC.
Peter Snyder, a University of Pennsylvania professor and a lead author and central architect of the Testosterone Trials, told AAMC that treatment benefits for confirmed low testosterone are modest. He also emphasized that treatment carries risks. His interpretation supports realistic expectations rather than an assumption that replacing testosterone will resolve every concern.
AAMC additionally cites a 2022 review that characterized benefits in carefully conducted randomized trials as modest. This is a description of earlier evidence cited by the explainer. It should not be presented as a new estimate produced by the October report.
The findings are still relevant to understanding treatment. They show why the discussion should identify a specific intended benefit rather than rely on a general promise of feeling younger or functioning better. Different outcomes need different evidence.
The Testosterone Trials studied men aged 65 and older with hypogonadism. Their results should not automatically be applied to younger adult men. A reader in his thirties or forties is not necessarily represented by a trial involving older participants.
Age is part of the study’s scope rather than a minor detail. The appropriate practical question is whether the evidence being discussed includes people whose circumstances resemble the patient’s own. Testostra’s coverage of treatment evidence for older men offers a related place to examine that distinction.
AAMC says the evidence does not establish consistent, significant benefits for people without hypogonadism. Benefits observed in diagnosed patients should therefore not be generalized to everyone seeking help with fatigue, mood or physical performance.
The report’s distinction is not between people who care about their health and people who do not. It is between clinical groups with different evidence behind treatment. An argument for treating confirmed deficiency does not automatically become an argument for prescribing testosterone to someone without it.
The AAMC explainer does not provide participant counts or effect sizes for the Testosterone Trials. Its summary therefore supports describing the direction of the reported findings, but not calculating the likely size of an individual reader’s benefit.
Physical function also remains a separate question. Shalender Bhasin of Brigham and Women’s Hospital and Harvard Medical School told AAMC that observed effects on physical performance are modest. He said meaningful benefits for frail or mobility-disabled people still need to be established in large randomized trials.
That distinction matters when claims move from a measured biological result to a promise about daily life. An outcome such as bone density should be described as that outcome. It should not be rewritten as proof that treatment broadly reduces disability or makes routine tasks easier.
AAMC notes that some older patients describe more energy or easier performance of basic functions. Such experiences are worth hearing, but they are not proof of broad treatment effectiveness. Personal accounts and controlled research answer different questions.
The explainer also describes research involving specific groups, including hypogonadal men with some cancers and men with spinal cord injuries. These investigations concern defined populations or unanswered safety questions. They are not evidence for expanding treatment to unrelated groups.
A useful approach to assessing emerging hormone evidence is to keep the population and measured outcome attached to the claim. This avoids turning a focused finding into a general recommendation.
The practical value of the AAMC explainer is a clearer set of questions. It separates the reason for considering treatment from the benefit someone hopes to receive. Those two issues need to be connected through clinical assessment rather than through advertising language.
Michael Irwig, an endocrinologist at Beth Israel Deaconess Medical Center and associate professor at Harvard Medical School, told AAMC that most cases of fatigue and erectile dysfunction are not due to low testosterone. He also described patients requesting treatment despite not testing low. His comments underline the importance of considering other explanations for symptoms.
For a discussion with a qualified clinician, useful questions include:
AAMC includes infertility among reported treatment risks in men who are not hypogonadal. For men who may want children, fertility deserves an explicit place in the conversation. The report should not be read as suggesting that testosterone treatment is automatically beneficial for reproduction simply because testosterone has a normal reproductive role.
It is also reasonable to ask how treatment response and adverse effects would be assessed. This keeps the conversation focused on observable outcomes rather than on obtaining a prescription as the endpoint. The answers belong to the clinician responsible for the individual’s care.
When evaluating promotional claims, the same approach helps: identify the proposed benefit, the diagnosis and the evidence. A claim that combines better mood with more muscle and greater energy needs support for each outcome. One favorable result is not evidence for the whole package.
Bottom line: The AAMC explainer does not introduce a new treatment guideline or report a new clinical trial. It does not justify an immediate broad change in medical practice. Its contribution is to clarify the difference between testosterone’s established functions and demonstrated treatment benefits, while keeping individual decisions within qualified clinical care.
A report about testosterone’s normal functions needs to be weighed against treatment findings before it becomes a reason to seek hormone therapy. Testostra helps readers sort clinical findings from promotional claims through clear coverage of TRT and emerging hormone research, without offering personal diagnosis or prescribing treatment.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra